COVID-19 Diagnostic Testing for Businesses

Creating a safer new normal for in-person workers

As our economies slowly re-open for business, we realize that new health protocols need to be implemented into workspaces so that our employees can return to their normal best without having to worry about their safety. Compromising on protecting employees returning to the work is just not an option.

Health protocols that are implemented into your workforce need to ensure that a safe environment is created for your employees so they can best do their tasks in an environment that prioritizes health and wellbeing.

We at Silverberry Genomix now provide end-to-end COVID-19 diagnostic testing services for businesses that want to safely bring back their workforce, accompanied by the peace of mind necessary to produce optimal results.


Our FDA-Authorized COVID-19 Diagnostic Test is as simple as it gets!

1. Testing will be done at designated locations.

2. Test will be conducted by a medical professional or self-taken with professional supervision via telehealth

3. Results are available within 24 hours of receiving the tests at lab

Through our COVID-19 Diagnostic Tests for your business, we want to help you create a layer of surveillance ensuring:

  • Systematic return of workforce

  • Timely containment of potential threats

  • Workforce wellbeing

Our services are available all across the United States!


Business Managers

Contact us to find out how we can implement our solution in your workspace!




Contact us if you're a medical provider looking to work with us!


  • This test has not been FDA cleared or approved;
  • This test has been authorized by FDA under an EUA for use by authorized laboratories;
  • This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
  • This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked.